N/A N=14 Advanced Image Guidance Utilized in Liver Surgery
Carcinoma, Hepatocellular
Primary: Successful Insertion of Ablation Antenna Into Target Lesion — 100 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=49 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
N/A N=57 Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
Liver Resection · Cancer
Primary: Changes in Liver Remnant Volume — 18.4; 80.7 percentage change
Phase 3 N=86 Usefulness of BiClamp Forceps for Liver Resection: A Randomized Clinical Trial
Hepatobiliary Disease
Primary: The Total Blood Loss — 376.73; 339.81 ml
N/A N=106 Hepatic Effects of Gastric Bypass Surgery
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
N/A N=54 Prospective Study of Liver Mobilization With the Levita Magnetic Surgical System
Bariatric Surgery Candidate
Primary: Number and Types of Additional Tools Required to Mobilize the Liver During Procedure — 0 Additional Tools to Mobilize Liver
N/A N=20 Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Adult Hepatocellular Carcinoma · Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma
Primary: Severe Treatment-related Toxicity — 0 Participants
N/A N=68 Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Liver Transection During Laparoscopic Liver Resection
Primary: Intraoperative Blood Loss — 195; 218 ml
N/A N=7 Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: The Safety of Hypofractionated Stereotactic Radiotherapy in Patients With Advanced Hepatocellular Carcinoma — 0; 0; 1; 3 Participants
Phase 2 N=56 A Study of Fibrocaps in Liver Surgery in the Netherlands
Postoperative Hemorrhage
Primary: Time to Hemostasis — 2.2; 4.4 minutes — p=0.004
Phase 4 N=100 Intraoperative Glucose Control in Liver Transplant
Liver Transplant
Primary: Infection Rates — 27; 26; 11; 7 Participants — p=0.841
N/A N=47 Clinical Safety and Performance of GATT-Patch in Open Liver Surgery
Hemorrhage, Surgical
Primary: Hemostasis — 38; 46 Participants
N/A N=20 Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery
Hepatocellular Injury · Blood Loss
Primary: Hepatocellular Damage Reflected by Liver Fatty-acid Binding Protein (L-FABP) Levels — 9097; 11,688 ng*h/mL
Phase 2 N=11 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
Phase 3 N=102 Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics
Liver Transplantation · Surgical Site Infection
Primary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants
N/A N=68 Ultrasound Liver Intraoperative Imaging With SonoVue®
Liver Metastases From Colorectal Primary Cancer
Primary: Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases. — 7.7 percentage of patients
Phase 2 N=146 A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
N/A N=51 Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
Liver Cancer
Primary: Proportion of Participants With Successful Control of Disease at 18 Months — .18 proportion of participants
N/A N=105 Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Phase 2 N=30 Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
N/A N=160 The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
Tissue Donors · Liver Transplantation · Ischemia Reperfusion Injury
Primary: Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days — 145; 152 IU/L
N/A N=3 Stereotactic Body Radiation Therapy (SBRT) for Liver Mets
Liver Metastases
Primary: Maximum Tolerated Dose (MTD) — 60 Gy
N/A N=153 Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
Liver Diseases
Primary: Pathological Yield Fragmentation — 14; 11; 13; 10 mm
Phase 3 N=135 Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
Liver Cancer
Primary: Postoperative Complications — 42; 45; 24; 24 Participants